Philip R. Cohen, MD
Dr. Cohen is from the University of Houston Health Center, Texas; the Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston; and the Department of Dermatology, University of Texas Medical School, Houston.
Dr. Cohen reports no conflicts of interest in relation to this post.
The June 2012 issue of Annals of Oncology (2012;23[suppl 5]:v6-v11) featured an abstract (L6.5) from the 4th WIN (Worldwide Innovative Networking in personalized cancer medicine) symposium on the efficacy of biomarkers and personalized cancer therapy that took place in Paris, France, on June 28 and 29, 2012. The authors provided an update on using personalized medicine for the treatment of a large cohort of oncology patients with advanced cancer. Complete molecular profiling of the patient’s tumor was performed and the patient was treated with matched therapy, when available, directed against the detected molecular aberration. The results were measured as a function of time to treatment failure and supported the use of a personalized molecular approach for patients with cancer. [More]